NCT03286712View on ClinicalTrials.gov

The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

May 31, 2017

Conditions
Chronic Kidney DiseaseAnemiaComplication of Peritoneal Dialysis
Interventions
DRUG

Renogen

Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity

Trial Locations (1)

1101

Department of Adult Nephrology; National Kidney and Transplant Institute, Quezon City

All Listed Sponsors
lead

National Kidney and Transplant Institute, Philippines

OTHER

NCT03286712 - The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients | Biotech Hunter | Biotech Hunter